Key facts
- This page summarizes Gail Cawkwell's Form 3 filing for Aclaris Therapeutics, Inc. (ACRS).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Jul 2022, 16:54.
Gail Cawkwell - 27 Jun 2022 Form 3 Insider Report for Aclaris Therapeutics, Inc. (ACRS)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ACRS
- Reported as of
- 27 Jun 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 05 Jul 2022, 16:54:56 UTC
- Prior SEC filing
- 15 Feb 2022
- Next SEC filing
- 05 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gail Cawkwell filed Form 3 for Aclaris Therapeutics, Inc. (ACRS) on 05 Jul 2022.
Change
- Previous filing in this sequence was filed on 15 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
No securities are beneficially owned. Exhibit 24.1 - Power of Attorney